EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Exploring the Association Between Lipid-Lowering Medications and Dry Eye Disease in COVID-19 Patients

Konstantin Yaakov Gushansky, Pinja Sutinen, Sohee Jeon, Raimo Tuuminen

romanian journal of ophthalmology · 2025

DOI: 10.22336/rjo.2025.82 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift romanian journal of ophthalmology, 2025. Verfasst von Konstantin Yaakov Gushansky und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Shaare Zedek Medical Center, Jerusalem, Israel. Hauptthemen laut MEDLINE: Dry Eye Syndromes, COVID-19, SARS-CoV-2, Hydroxymethylglutaryl-CoA Reductase Inhibitors. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To explore the associations between systemic lipid-lowering medications and dry eye disease (DED) in patients hospitalized for SARS-CoV-2.

Methods

This retrospective cohort study analyzed electronic medical records of SARS-CoV-2 patients hospitalized at Shaare Zedek Medical Center from April 1, 2020, to December 31, 2024. Adults without a previous DED diagnosis who had an ophthalmologic examination confirming no DED within the year preceding hospitalization were included. Exclusions included ICU admissions, specific systemic conditions, ocular surgeries, and systemic medications known to induce DED. Patients were categorized into those who developed DED within six months post-hospitalization and those who did not.

Results

Among the 1,165 patients, 167 (14.3%) developed DED post-hospitalization. After adjusting for age, gender, and SARS-CoV-2 vaccination status, an inverse association between statins and dry eye disease was evident. Treatment with any statin was associated with reduced odds of developing dry eye disease (OR 0.289, p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dry Eye SyndromesCOVID-19SARS-CoV-2Hydroxymethylglutaryl-CoA Reductase InhibitorsHypolipidemic AgentsHumansRetrospective StudiesFemaleMaleMiddle AgedAgedRisk Factors

Stichwörter der Autor:innen

COVID-19COVID-19 = Coronavirus disease 2019DED = Dry eye diseaseHMG-CoA = 3-Hydroxy-3-methylglutaryl-CoAHMG-CoA reductase inhibitorsICU = Intensive care unitOR = Odds ratioSARS-CoV-2SARS-CoV-2 = Severe acute respiratory syndrome coronavirus 2dry eye diseasestatinssystemic medication

Substanzen

Hydroxymethylglutaryl-CoA Reductase InhibitorsHypolipidemic Agents

Autor:innen und Institutionen

  • Department of Ophthalmology, Shaare Zedek Medical Center, Jerusalem, Israel.
  • Helsinki Retina Research Group, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
  • Keye Eye Center, 326 Teheran-ro, Gangnam-gu, Seoul, South Korea.
  • Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
  • Department of Ophthalmology, Kymenlaakso Central Hospital, Kotka, Finland.

Zitieren

APA

Gushansky, K. Y., Sutinen, P., Jeon, S., & Tuuminen, R. (2025). Exploring the Association Between Lipid-Lowering Medications and Dry Eye Disease in COVID-19 Patients. romanian journal of ophthalmology. https://doi.org/10.22336/rjo.2025.82

Vancouver

Gushansky KY, Sutinen P, Jeon S, Tuuminen R. Exploring the Association Between Lipid-Lowering Medications and Dry Eye Disease in COVID-19 Patients. romanian journal of ophthalmology. 2025. doi:10.22336/rjo.2025.82

BibTeX
@article{Gushansky2025,
  author = {Gushansky, Konstantin Yaakov and Sutinen, Pinja and Jeon, Sohee and Tuuminen, Raimo},
  title = {Exploring the Association Between Lipid-Lowering Medications and Dry Eye Disease in COVID-19 Patients},
  journal = {romanian journal of ophthalmology},
  year = {2025},
  doi = {10.22336/rjo.2025.82}
}
Kostenlos starten →